Moderna (MRNA) stock fell 4.6% Friday despite breakthrough cancer vaccine results. Analysts project $3B sales by 2035. Price targets range $74-$135. The post Moderna (MRNA) Stock Drops 4.6% Despite Groundbreaking Cancer Vaccine Breakthrough appeared first on Blockonomi.